Skip to main content
Log in

Multiple myeloma gammopathies

Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015;125:2068–74.

    Article  CAS  Google Scholar 

  2. Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 2019;34:224–33.

    Article  Google Scholar 

  3. Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood 2016;127:1109–16.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sonja Zweegman.

Ethics declarations

Conflict of interest

CAMS, BvdH, AGD, M-DL, U-HM, and AW have no competing financial interests. SZ received research funding from Celgene, Takeda, and Janssen and participated in advisory boards from Celgene, Takeda, Janssen, and Sanofi. NWCJvdD received research funding from Celgene, BMS, and Janssen and participated in advisory boards from Celgene, Takeda, Janssen, Sanofi, and BMS. PS received research funding from Celgene, Janssen, and Amgen and participated in advisory boards from Celgene, Janssen, and Amgen. The HOVON87/NMSG18 study was partly funded by Celgene.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stege, C.A.M., van der Holt, B., Dinmohamed, A.G. et al. Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. Leukemia 34, 1964–1966 (2020). https://doi.org/10.1038/s41375-020-0713-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-020-0713-4

  • Springer Nature Limited

This article is cited by

Navigation